Navigation Links
ShangPharma Appoints Pharmaceutical Executive Dr. Mitchell Reff Chief Biologics Officer

SHANGHAI, Jan. 13, 2014 /PRNewswire/ -- ShangPharma Corporation is pleased to announce that Dr. Mitchell Reff has joined the company as Chief Biologics Officer. Dr. Reff brings over 30 years of research and development experience in the biopharmaceutical industry. Dr. Reff's appointment further strengthens the world-class technical capabilities of ChemPartner's Biologics Division and offers Pharmaceutical and Biotechnology companies from around the world first-rate strategic and technical expertise to discover and manufacture novel first-in-class and best-in-class biologic clinical development candidates to advance into the Pharmaceutical and Biotechnology company pipelines.

Dr. Reff received his Ph.D. in Medical Microbiology from Stanford University School of Medicine, and his Bachelor's degree in Chemistry from Massachusetts Institute of Technology. This was followed by a  Postdoctoral Fellowship at Harvard Medical School, and  a position at the National Cancer Institute. Dr. Reff then spent 8 years at SmithKline Laboratories working on gene expression in mammalian cells and protein engineering. After that, he joined Idec Pharmaceuticals as head of molecular biology in 1990. Dr. Reff had a distinguished 21 year career at Idec, and later at Biogen Idec. He was Vice President Discovery Oncology at Biogen Idec running multiple bicoastal oncology groups developing small molecule and recombinant protein therapeutic molecules for oncology and delivered 6 novel oncology drugs into clinical trials in 5 years.

In early 1990s, Dr. Reff was Project Leader targeting B cell lymphoma, building and expressing the chimeric mouse-human anti-CD20 monoclonal antibody (Rituxan), the first monoclonal antibody approved to treat a tumor. Dr. Reff led the efforts from discovery until Rituxan entered its pivotal clinical trial.

Dr. Reff is well-recognized in the pharmaceutical and research community having been listed as an inventor on approximately 29 patents and patent applications, and as an author in nearly 100 scientific publications and presentations.

About ShangPharma:

ShangPharma Corp is a leading contract research organization (CRO) providing a broad range of high-quality, integrated services across both drug discovery and drug development to help pharmaceutical and biotechnology companies discover and develop novel drug candidates efficiently. The Company today has a team of nearly 2,000 skilled scientists in 1 million square feet of state-of-the-art research facilities and office space. For more information, please visit: ChemPartner is a wholly owned subsidiary of ShangPharma Corp and also the main brand of the group.

SOURCE ShangPharma
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. ShangPharma Corporation Announces Completion of Merger
2. ShangPharma Corporation Announces Extraordinary General Meeting of Shareholders
3. ShangPharma Announces Third Quarter 2012 Results
4. ShangPharma to Report Third Quarter 2012 Financial Results on November 20, 2012
5. ShangPharma and Harbour Antibodies Announce Licensing Agreement
6. ShangPharma Announces Second Quarter 2012 Results
7. ShangPharma to Report Second Quarter 2012 Financial Results on August 20, 2012
8. ShangPharma Independent Committee Appoints Financial Advisor
9. ShangPharma Independent Committee Appoints Chairman and Legal Counsel
10. ShangPharma Announces Receipt of "Going Private" Proposal at $8.50 to $9.50 Per ADS
11. ShangPharma Announces First Quarter 2012 Results
Post Your Comments:
(Date:10/13/2015)... 2015  SRI International has been awarded a ... five years by the National Institute of Allergy ... Institutes of Health, for the development of products ... of radiation exposure. Under this multi-year contract, ... will provide services, facilities, expertise and capabilities to ...
(Date:10/13/2015)... 2015 ) ... & European markets for Meniscal Repair - 16 ... --> ) has announced the addition ... Meniscal Repair - 16 Countries (2010-2021)" report ... Markets ( ) has announced the addition ...
(Date:10/13/2015)... 2015  Graduate students across the country, with ... will soon have the opportunity to learn about ... drug discovery and development process. Eli Lilly and ... 10 leaders from academic institutions to create an ... of Drug Development."  Lilly will formally unveil the ...
Breaking Medicine Technology:
(Date:10/13/2015)... ... ... The American Institutes for Research ( AIR ) developed a collection of ... experienced sexual assault and other trauma. The toolkit, funded by the U.S. Department of ... Act's 21st anniversary. , AIR developed the Safe Place toolkit ...
(Date:10/13/2015)... ... , ... Vision Group Holdings, the largest LASIK provider in North America, announced ... LASIK Vision Institute and TLC Laser Eye Centers, Vision Group Holdings has performed more ... , Global Laser Vision will continue to operate in San Diego as it has ...
(Date:10/13/2015)... ... October 13, 2015 , ... Sir Grout of Greater ... the local Boston chapter of Ronald McDonald House Charities® (RMHC®). This donation was made ... Sir Grout of Greater Boston since its inception. , “We believe strongly in the ...
(Date:10/13/2015)... ... October 13, 2015 , ... CURE Media ... today announced a new partnership with the International Waldenstrom’s Macroglobulinemia Foundation (IWMF) ... non-Hodgkin’s lymphoma, their families and physicians. , “Waldenstrom’s Macroglobulinemia is a so-called ...
(Date:10/13/2015)... ... October 13, 2015 , ... "My friend's son suffers from ... his infected cheeks," said an inventor from Platteville, Colo. "I came up with this ... He developed the UNTOUCHABLE to prevent a child from rubbing or scratching his or ...
Breaking Medicine News(10 mins):